Linezolid for infective endocarditis: A structured approach based on a national database experience.
No Thumbnail Available
Identifiers
Date
2021
Authors
Muñoz, P
De la Villa, S
Martínez-Sellés, M
Goenaga, M A
Reviejo-Jaka, K
Revillas, F Arnáiz de Las
García-Cuello, L
Hidalgo-Tenorio, C
Rodríguez-Esteban, M A
Antorrena, I
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Current data on the frequency and efficacy of linezolid (LNZ) in infective endocarditis (IE) are based on small retrospective series. We used a national database to evaluate the effectiveness of LNZ in IE.This is a retrospective study of IE patients in the Spanish GAMES database who received LNZ. We defined 3 levels of therapeutic impact: LNZ 50% of the total treatment, and > 50% of the LNZ doses prescribed in the first weeks of treatment), and LNZ ≥ 7 days not fulfilling the high-impact criteria (LNZ-NHI). Effectiveness of LNZ was assessed using propensity score matching and multivariate analysis of high-impact cases in comparison to patients not treated with LNZ from the GAMES database matched for age-adjusted comorbidity Charlson index, heart failure, renal failure, prosthetic and intracardiac IE device, left-sided IE, and Staphylococcus aureus. Primary outcomes were in-hospital mortality and one-year mortality. Secondary outcomes included IE complications and relapses.From 3467 patients included in the GAMES database, 295 (8.5%) received LNZ. After excluding 3 patients, 292 were grouped as follows for the analyses: 99 (33.9%) patients in LNZ 50% of the LNZ doses prescribed in the first weeks of treatment), and LNZ ≥ 7 days not fulfilling the high-impact criteria (LNZ-NHI). Effectiveness of LNZ was assessed using propensity score matching and multivariate analysis of high-impact cases in comparison to patients not treated with LNZ from the GAMES database matched for age-adjusted comorbidity Charlson index, heart failure, renal failure, prosthetic and intracardiac IE device, left-sided IE, and Staphylococcus aureus. Primary outcomes were in-hospital mortality and one-year mortality. Secondary outcomes included IE complications and relapses.From 3467 patients included in the GAMES database, 295 (8.5%) received LNZ. After excluding 3 patients, 292 were grouped as follows for the analyses: 99 (33.9%) patients in LNZ
Description
MeSH Terms
Aged
Anti-Bacterial Agents
Endocarditis
Endocarditis, Bacterial
Female
Hospital Mortality
Humans
Linezolid
Male
Middle Aged
Retrospective Studies
Staphylococcal Infections
Staphylococcus aureus
Treatment Outcome
Anti-Bacterial Agents
Endocarditis
Endocarditis, Bacterial
Female
Hospital Mortality
Humans
Linezolid
Male
Middle Aged
Retrospective Studies
Staphylococcal Infections
Staphylococcus aureus
Treatment Outcome